The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Silymarin Modulates Cisplatin-Induced Oxidative Stress and Hepatotoxicity in Rats
Open accessAbstract
Cisplatin (CDDP) is a widely used anticancer drug, but at high dose, it can produce undesirable side effects such as hepatotoxicity. Because silymrin has been used to treat liver disorders, the protective effect of silymarin on CDDP-induced hepatotoxicity was evaluated in rats. Hepatotoxicity was determined by changes in serum alanine aminotransferase [ALT] and aspartate aminotransferase [AST], nitric oxide [NO] levels, albumin and calcium levels, and superoxide dismutase [SOD], glutathione peroxidase [GSHPx] activities, glutathione content, malondialdehyde [MDA] and nitric oxide [NO] levels in liver tissue of rats. Male albino rats were divided into four groups, 10 rats in each. In the control group, rats were injected i.p. with 0.2 ml of propylene glycol in saline 75/25 (v/v) for 5 consecutive days [Silymarin was dissolved in 0.2 ml of propylene glycol in saline 75/25 v/v]. The second group were injected with CDDP (7.5 mg /kg, I.P.), whereas animals in the third group were i.p. injected with silymarin at a dose of 100 mg/kg/day for 5 consecutive days. The Fourth group received a daily i.p. injection of silymarin (100 mg/kg/day for 5 days) 1 hr before a single i.p. injection of CDDP (7.5 mg/kg). CDDP hepatotoxicity was manifested biochemically by an increase in serum ALT and AST, elevation of MDA and NO in liver tissues as well as a decrease in GSH and the activities of antioxidant enzymes, including SOD, GSHPx in liver tissues. In addition, marked decrease in serum NO, albumin and calcium levels were observed. Serum ALT, AST, liver NO level, MDA was found to decreased in the combination group in comparison with the CDDP group. The activities of SOD, GSHPx, GSH and serum NO were lower in CDDP group than both the control and CDDP pretreated with silymarin groups. The results obtained suggested that silymarin significantly attenuated the hepatotoxicity as an indirect target of CDDP in an animal model of CDDP-induced nephrotoxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
[30] Microsomal lipid peroxidation
Buege, J. A., & Aust, S. D. (1978) · Methods in Enzymology · doi:10.1016/s0076-6879(78)52032-6 · Cited by 13,343
Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide.
Ignarro, L. J., Buga, G. M., Wood, K. S., Byrns, R. E., & Chaudhuri, G. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.24.9265 · Cited by 5,074
Glutathione peroxidase activity in selenium-deficient rat liver
Lawrence, R. A., & Burk, R. F. (1976) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(76)90747-6 · Cited by 3,528
Wendel, A. (1981) · Methods in Enzymology · doi:10.1016/s0076-6879(81)77046-0 · Cited by 3,009
A simplified assay method of superoxide dismutase activity for clinical use
Masayasu, M., & Hiroshi, Y. (1979) · Clinica Chimica Acta · doi:10.1016/0009-8981(79)90211-0 · Cited by 557
Iron metabolism, free radicals, and oxidative injury
Emerit, J., Beaumont, C., & Trivin, F. (2001) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(01)00068-3 · Cited by 456
Pathophysiological Basis for Antioxidant Therapy in Chronic Liver Disease
Medina, J., & Moreno-Otero, R. (2005) · Drugs · doi:10.2165/00003495-200565170-00003 · Cited by 216
Scavenging of reactive oxygen species by silibinin dihemisuccinate
Mira, L., Silva, M., & Manso, C. F. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90053-1 · Cited by 192
Silymarin increases antioxidant enzymes in alloxan-induced diabetes in rat pancreas
Soto, C., Recoba, R., Barrón, H., Alvarez, C., & Favari, L. (2003) · Comparative Biochemistry and Physiology Part C: Toxicology & Pharmacology · doi:10.1016/s1532-0456(03)00214-x · Cited by 188
Enzymatic studies of cisplatin induced oxidative stress in hepatic tissue of rats
Pratibha, R., Sameer, R., Rataboli, P. V., Bhiwgade, D. A., & Dhume, C. Y. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.01.007 · Cited by 173
Wang, G., Reed, E., & Li, Q. (2004) · Oncology Reports · doi:10.3892/or.12.5.955 · Cited by 170
Selectivity of Silymarin on the Increase of the Glutathione Content in Different Tissues of the Rat
Valenzuela, A., Aspillaga, M., Vial, S., & Guerra, R. (1989) · Planta Medica · doi:10.1055/s-2006-962056 · Cited by 162
Flavonoid Antioxidant Silymarin and Skin Cancer
Singh, R. P., & Agarwal, R. (2002) · Antioxidants and Redox Signaling · doi:10.1089/15230860260220166 · Cited by 140
Nitric Oxide and Some Nitric Oxide Donor Compounds Enhance the Cytotoxicity of Cisplatin
Wink, D. A., Cook, J. A., Christodoulou, D., Krishna, M. C., Pacelli, R., Kim, S., DeGraff, W., Gamson, J., Yoram Vodovotz, B., Russo, A., et al. (1997) · Nitric Oxide · doi:10.1006/niox.1996.0108 · Cited by 133
Saad, S. Y., Najjar, T. A. O., & Alashari, M. (2004) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2004.04127.x · Cited by 123
Silybin, a new iron-chelating agent
Borsari, M., Gabbi, C., Ghelfi, F., Grandi, R., Saladini, M., Severi, S., & Borella, F. (2001) · Journal of Inorganic Biochemistry · doi:10.1016/s0162-0134(01)00198-2 · Cited by 122
Increased Plasma Endothelin-1 and Cardiac Nitric Oxide during Doxorubicin-Induced Cardiomyopathy
Sayed‐Ahmed, M. M., Khattab, M. M., Gad, M. Z., & Osman, A. M. (2001) · Pharmacology & Toxicology · doi:10.1034/j.1600-0773.2001.d01-148.x · Cited by 91
Kim, S.-H. (2004) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2004.01.002 · Cited by 86
Yılmaz, H. R., Söğüt, S., Özyurt, B., Özuğurlu, F., Şahin, Ş., Işık, B., Uz, E., & Özyurt, H. (2005) · Toxicology and Industrial Health · doi:10.1191/0748233705th216oa · Cited by 76
Hasegawa, T., Kaneko, F., & Niwa, Y. (1992) · Life Sciences · doi:10.1016/0024-3205(92)90550-9 · Cited by 69
Saad, S. Y., Najjar, T. A. O., Daba, M. H., & Al‐Rikabi, A. C. (2002) · Chemotherapy · doi:10.1159/000069714 · Cited by 59
Preventive effect of silymarin against taurolithocholate-induced cholestasis in the rat
Crocenzi, F. A., Pozzi, E. J. S., Pellegrino, J. M., Garay, E. A. R., Mottino, A. D., & Roma, M. G. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00253-3 · Cited by 25
., A. R. M. A. G., ., S. E. A., & ., S. A. A. O. (2001) · Pakistan Journal of Biological Sciences · doi:10.3923/pjbs.2001.604.607 · Cited by 11
Silymarin-induced mitochondrial Ca2+ release
Chávez, E., & Bravo, C. (1988) · Life Sciences · doi:10.1016/0024-3205(88)90542-5 · Cited by 8
Cited by
Cisplatin in cancer therapy: Molecular mechanisms of action
Dasari, S., & Bernard Tchounwou, P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.025 · Cited by 5,537
Silymarin as a Natural Antioxidant: An Overview of the Current Evidence and Perspectives
Surai, P. (2015) · Antioxidants · doi:10.3390/antiox4010204 · Cited by 738
Advances in Toxicological Research of the Anticancer Drug Cisplatin
Qi, L., Luo, Q., Zhang, Y., Jia, F., Zhao, Y., & Wang, F. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00204 · Cited by 440
Metadata
- Authors
- Mansour, H. H., Hafez, H. F., & Fahmy, N. M.
- Venue
- BMB Reports
- Published
- 2006-11-30
- Volume
- 39
- Issue
- 6
- Pages
- 656-661
- ISSN
- 1976-6696 (ISSN-L)
- OpenAlex
- W2020168919
- Cited by
- 269
- References
- 24
- FWCI
- 6.44
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.